Core Viewpoint - Eddy Pharmaceutical (688488) has seen a significant stock price increase of 22.17% this week, closing at 21.6 yuan, with a market capitalization of 9.089 billion yuan as of January 16, 2026 [1] Trading Information Summary - Eddy Pharmaceutical reached a maximum price of 22.11 yuan on January 16, 2026, marking a near one-year high, and was listed on the Shanghai and Shenzhen Stock Exchanges' "Dragon and Tiger List" due to a price increase of 15% on January 14, 2026 [1][4] - The company’s Vice President Wang Guangrong, Yu Ke, and non-independent director Liu Yan faced regulatory measures from the Shanghai Stock Exchange for information disclosure violations [1][4] Company Announcement Summary - On January 13, 2026, Eddy Pharmaceutical's board approved a plan to issue A-shares to specific investors, aiming to raise no more than 185 million yuan for acquiring a 22.2324% stake in Nanjing Nanda Pharmaceutical and for supplementing working capital [1][4] - The company plans to acquire the minority stake in Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [2][4] - The board also decided to terminate the previous plan for a 2024 A-share issuance to specific investors [1][5] Fundraising and Financial Strategy - The total amount to be raised from the new issuance is capped at 185 million yuan, with 130 million yuan allocated for the acquisition and 55 million yuan for working capital [3][6] - The company has outlined a three-year shareholder dividend plan, committing to distribute at least 10% of the annual distributable profits in cash, with a cumulative cash dividend of no less than 30% of the average distributable profits over the past three years [2]

Group 1 - Eddie Pharmaceuticals' stock price increased by 5.15% on January 16, reaching 22.06 CNY per share, with a trading volume of 520 million CNY and a turnover rate of 6.05%, resulting in a total market capitalization of 9.282 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 24.14% during this period [1] - The company, established on December 15, 2009, and listed on July 20, 2020, focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: human-derived proteins 41.11%, new drugs 35.69%, diagnostic equipment and reagents 13.62%, generic drugs 9.47%, and others 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceuticals, the Xingsheng Global Fund has a fund that entered the top ten in the third quarter, holding 6.229 million shares, which accounts for 1.48% of the circulating shares [2] - The estimated floating profit for today is approximately 6.7273 million CNY, with a total floating profit of 25.4142 million CNY during the three-day increase [2] - The Xingsheng Global Fund's mixed fund (LOF) A (163415) was established on December 18, 2012, with a latest scale of 14.567 billion CNY, yielding 6.54% this year, ranking 2504 out of 8847 in its category, and 48.84% over the past year, ranking 2241 out of 8094 [2]

Core Insights - The economic vitality of Yangzhou has surged since the reform and opening-up, with a significant rise in private entrepreneurs who have created notable business legends [1] - The total wealth of the top ten billionaires in Yangzhou has reached 56.1 billion RMB, with two individuals surpassing 10 billion RMB and two newcomers making their debut on the list [1] Group 1: Top Billionaires - The richest individual is Liang Qin, chairman of Yangjie Electronics Technology, with a net worth of 16 billion RMB, ranking 411th nationally [4] - Zhu Daqing, chairman of Tianfu Long Group, ranks second with a net worth of 13 billion RMB, marking his first appearance on the list [7] - Zhu Yinghui, holding 36.17% of Rongtai Co., ranks third with a net worth of 5.5 billion RMB, also making her debut on the list [8] Group 2: Notable Achievements - Zhou Guangrong, chairman of Haichang New Materials, has a combined net worth with his wife of approximately 5.3 billion RMB, leading a prominent powder metallurgy company [10] - Fu Helian, chairman of Aidi Pharmaceutical Group, is the highest-educated billionaire on the list, focusing on innovative drug development [11] - Zou Weimin, chairman of Chuan Yi Technology, has a net worth of about 3.1 billion RMB, having established a successful company in the notebook industry [12] Group 3: Emerging Entrepreneurs - Li Hongqing, former actual controller of Aoliwei Sensor, has a net worth of at least 3.8 billion RMB, having taken control of the company through capital operations [14] - Zhang Wensheng, chairman of Beijiajie Group, has a net worth of around 2.4 billion RMB, having built a leading company in oral care products [15] - Lin Mingwen, chairman of Yangzhou Jinqiu Tourism Products, has a net worth of approximately 1.5 billion RMB, becoming a major player in outdoor equipment manufacturing [17] Group 4: Young Entrepreneurs - Zhu Xingrong, general manager of Tianfu Long Group and the youngest billionaire at 42, holds a 13.14% stake in the company with a net worth of about 2.3 billion RMB [19] - Over half of the top ten billionaires started from grassroots sales or technical positions, demonstrating their ability to seize opportunities in industry transformation [19]

Core Viewpoint - Jiangsu Aidi Pharmaceutical (688488.SH) announced a plan to acquire minority shareholder equity in its subsidiary, Nanjing Nanda Pharmaceutical, which will increase its direct shareholding from 51.13% to 73.36% [1][3] Group 1: Acquisition Details - Aidi Pharmaceutical plans to raise up to 185 million yuan through a simplified procedure to fund the acquisition, with 130 million yuan allocated for acquiring 22.23% of Nanda Pharmaceutical's equity and 55 million yuan for working capital [1] - The acquisition is expected to enhance Aidi's control over Nanda Pharmaceutical and optimize financial performance, maximizing synergies between the two companies [4][10] Group 2: Market Potential - The demand for stroke treatment is anticipated to surge, with acute ischemic stroke cases in China projected to rise from 4.1 million in 2023 to 4.9 million by 2027 [4] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035 [4] Group 3: Product Pipeline - Aidi's new drugs, AD108 injection and ADB116 injection, are positioned to become significant profit growth drivers, targeting acute ischemic stroke treatment [4] - Aidi's HIV drug, Enomirac, has shown strong sales potential, with revenue from HIV drugs reaching 211 million yuan in the first three quarters of 2025, a 57.12% increase year-on-year [6][7] Group 4: International Expansion - Aidi Pharmaceutical is accelerating its international market expansion, with its HIV drug Enomirac approved for sale in Zanzibar, marking a significant milestone for Chinese-developed HIV drugs in Africa [9] - The company is also advancing its pipeline of innovative drugs, including a new HIV integrase inhibitor and long-acting pre-exposure prophylaxis drugs, which are in various stages of clinical trials [10]

Group 1 - The core point of the article is that Jiangsu Aidi Pharmaceutical Group announced a plan to raise up to 185 million yuan through a simplified procedure for issuing A-shares, primarily to acquire a 22.23% stake in its subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. for approximately 130.06 million yuan and to supplement working capital with 55 million yuan [1][2] - The chairman of Aidi Pharmaceutical, Fu Helian, stated that this move is a significant step towards focusing on the core business and enhancing competitive strength, aimed at long-term strategic development [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, being one of the few companies in China that holds production licenses for both raw materials and injectable formulations [1] Group 2 - Aidi Pharmaceutical previously acquired a 19.96% stake in Nanda Pharmaceutical in July 2022 and plans to further purchase an additional 31.16% stake in 2024, thereby gaining control over Nanda Pharmaceutical [2] - The acquisition of the additional 22.23% stake will enhance Aidi Pharmaceutical's control over Nanda Pharmaceutical, promoting strategic management upgrades and improving financial performance [2] - Aidi Pharmaceutical has maintained rapid growth in the HIV treatment sector for three consecutive years and is focused on advancing its core research pipeline and establishing a comprehensive commercialization system for new HIV drugs [2]

Group 1 - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and supplementing working capital [1] - The acquisition will increase the company's direct stake in Nanda Pharmaceutical to 73.358%, which is expected to enhance the company's performance and support its integrated strategy of "raw materials + formulations" [2] - Nanda Pharmaceutical is one of the few companies in China with both raw material and formulation approvals for urokinase, which will help the company extend its human protein product business into downstream finished formulations [2] Group 2 - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, highlighting its core technological advantages and product first-mover advantages in the anti-HIV field [3] - The current pipeline includes two approved first-class new drugs and ongoing clinical trials for ACC017, which is in Phase III, along with other promising candidates in HIV prevention [3] - The company maintains a "buy" rating, with profit forecasts for 2025-2027 being 0.07 billion, 0.89 billion, and 1.66 billion yuan respectively, not accounting for the impact of the upcoming share issuance [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [6]. Core Insights - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and for supplementing working capital [6]. - The acquisition of Nanda Pharmaceutical is expected to enhance the company's integrated strategy of "raw materials + formulations," increasing its direct stake to 73.358% [6]. - The company has a robust pipeline of human-derived protein products, including new drugs AD010, AD108, and ADB116, with AD108 and ADB116 receiving clinical approval in 2025 [6]. - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, highlighting its competitive edge in the HIV treatment market [6]. Financial Data and Profit Forecast - Total revenue is projected to grow from 418 million yuan in 2024 to 1.263 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 26.7% [5]. - The net profit is expected to turn positive in 2025, reaching 7 million yuan, and further increasing to 166 million yuan by 2027, reflecting a significant growth trajectory [5]. - The gross margin is forecasted to improve from 54.9% in 2024 to 75.2% in 2027, indicating enhanced operational efficiency [5]. - The return on equity (ROE) is anticipated to rise from -14.4% in 2024 to 13.4% in 2027, suggesting a recovery in profitability [5].

Group 1 - Eddie Pharmaceutical's stock increased by 5.12%, reaching 17.86 CNY per share, with a trading volume of 74.09 million CNY and a turnover rate of 1.02%, resulting in a total market capitalization of 7.515 billion CNY [1] - The company, established on December 15, 2009, and listed on July 20, 2020, is located in Yangzhou, Jiangsu Province, and focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of Eddie Pharmaceutical includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment, reagents, and others at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - Among the top ten circulating shareholders of Eddie Pharmaceutical, a fund under Huatai-PineBridge holds 4.6607 million shares, accounting for 1.11% of the circulating shares, with an estimated floating profit of approximately 4.0548 million CNY [2] - The Huatai-PineBridge Medical Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY, achieving a year-to-date return of 10.43% and a one-year return of 41.9% [2] - The fund ranks 654 out of 8838 in year-to-date performance and 3211 out of 8089 in one-year performance, with a cumulative return of 171.57% since inception [2]

中国经济网北京1月14日讯 艾迪药业(688488.SH)昨晚披露了关于终止公司2024年度向特定对象发行 A股股票的公告和2026年度以简易程序向特定对象发行A股股票预案。 艾迪药业于2026年1月13日召开第三届董事会第十一次会议，审议通过了《关于终止公司2024年度 向特定对象发行A股股票事项的议案》等相关议案，公司决定终止2024年度向特定对象发行A股股票事 项，本事项无需提交公司股东会审议。 艾迪药业2024年8月12日召开第二届董事会第二十五次会议、第二届监事会第二十四次会议，审议 通过了《关于公司2024年度向特定对象发行A股股票方案的议案》等相关议案，同意公司拟向傅和亮发 行不超过14,534,883股（含本数）股份，募集资金总额不超过10,000.00万元（含本数），扣除相关发行 费用后的募集资金净额全部拟用于补充流动资金。傅和亮为公司实际控制人之一。傅和亮，男，中国国 籍，拥有加拿大居留权。 艾迪药业表示，自公司披露2024年度向特定对象发行A股股票事项以来，公司一直在积极推进各项 工作，并严格按照相关法律法规和规范性文件要求履行了决策程序和信息披露义务。 截至目前，公司拟开展2026年度 ...

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and for supplementing working capital [6] - The acquisition will increase the company's direct stake in Nanda Pharmaceutical to 73.358%, which is expected to enhance the company's performance as Nanda reported a net profit of 55.81 million yuan from January to October 2025 [6] - The company is advancing its human-derived protein product pipeline, including new drugs AD010, AD108, and ADB116, with AD108 receiving clinical approval in 2025 for treating acute ischemic stroke [6] - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, indicating its commitment to becoming a leading brand in HIV innovation while expanding into international markets [6] Financial Summary - Projected total revenue for 2025 is 806 million yuan, with a year-on-year growth rate of 92.8% [5] - Expected net profit for 2025 is 7 million yuan, with a significant increase projected to 89 million yuan in 2026 and 166 million yuan in 2027 [5] - The gross margin is expected to improve from 63.2% in 2025 to 75.2% in 2027 [5]